Adjuvant breast cancer: which clinical and pathological characteristics in 2007?

被引：8
作者：
Penault-Llorca, F. [1 ,2 ]
Arnould, L. [3 ]
机构：
[1] Ctr Jean Perrin, Serv Anatomopathol, F-63011 Clermont Ferrand, France
[2] Univ Auvergne, Fac Med & Pharm, EA 4233, F-63000 Clermont Ferrand, France
[3] Ctr Reg Lutte Canc Bourgogne, Ctr GF Leclerc, Serv Pathol, F-21000 Dijon, France
来源：
BULLETIN DU CANCER | 2010年 / 97卷 / 12期
关键词：
epidemiology; breast cancer; HER2; gene; cancer stage; SURVIVAL; HER-2; IMMUNOHISTOCHEMISTRY; AMPLIFICATION; EXPRESSION; FREQUENCY; RECEPTOR;
D O I：
10.1684/bdc.2010.1223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To refine available epidemiological data in early breast cancer, a national and retrospective study analyzed 1,934 cases listed between May and July 2007 by 88 French centers. More than one third of patients had less than 50 years old (26%) or more than 74 (15%). The anatomopathological tumors' characteristics were as following: <= 2 cm in 62% of cases, lymphatic invasion in 35% of cases, positive hormone receptors in 85% of cases, and SBR grade III in 18% of cases. The assessment of HER2 status, performed in 1,899 cases (98%), showed at least 12.1% of early stage HER2 positive tumors. HER2 overexpression was higher before 50 years old (15.9 versus 11.5% between 50 and 70 years, and 10.0% if >= 70 years old), for the largest tumors (pT2/3/4: 15.9%, < 1 cm: 11.4%, between 1 and 2 cm: 9.0%) or for a high SBR grade (III: 24.7%, II: 12.1%, I: 3.5%). This study allowed to emphasize the prevalence of HER2 overexpression in elderly patients and for small size tumors.
引用
收藏
页码：1421 / 1426
页数：6
相关论文
共 27 条
  • [1] Acosta G., 2001, European Journal of Cancer, V37, pS241, DOI 10.1016/S0959-8049(01)81382-4
  • [2] [Anonymous], B EPIDEMIOLOGIQUE HE
  • [3] Mammography of ductal carcinoma in situ of the breast:: Review of 909 cases with radiographic-pathologic correlations
    Barreau, A
    de Mascarel, I
    Feuga, C
    MacGrogan, G
    Dilhuydy, MH
    Picot, W
    Dilhuydy, JM
    de Lara, CT
    Bussières, E
    Schreer, I
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2005, 54 (01) : 55 - 61
  • [4] BAUDIER F, 2007, BEH, V17, P142
  • [5] CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
  • [6] 2-H
  • [7] Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
    Chia, Stephen
    Norris, Brian
    Speers, Caroline
    Cheang, Maggie
    Gilks, Blake
    Gown, Allen M.
    Huntsman, David
    Olivotto, Ivo A.
    Nielsen, Torsten O.
    Gelmon, Karen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) : 5697 - 5704
  • [8] The new generation of breast cancer clinical trials: the right drug for the right target
    De Azambuja, Evandro
    Cardoso, Fatima
    Meirsman, Livia
    Straehle, Carolyn
    Dolci, Stella
    Vantongelen, Kris
    Piccart-Gebhart, Martine
    [J]. BULLETIN DU CANCER, 2008, 95 (03) : 352 - 357
  • [9] Radiological features and pathological-biological correlations in 348 women with breast cancer under 35 years old
    Di Nubila, Brunella
    Cassano, Enrico
    Urban, Linei A. B. D.
    Fedele, Palmina
    Abbate, Francesca
    Maisonneuve, Patrick
    Veronesi, Paolo
    Renne, Giuseppe
    Bellorni, Massimo
    [J]. BREAST, 2006, 15 (06) : 744 - 753
  • [10] Estimates of the cancer incidence and mortality in Europe in 2006
    Ferlay, J.
    Autier, P.
    Boniol, M.
    Heanue, M.
    Colombet, M.
    Boyle, P.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (03) : 581 - 592
123